Organization
The University of Utah Huntsman Cancer Institute, Salt Lake City, UT
5 abstracts
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.Org: HealthTree Foundation, Janssen Scientific Affairs, Janssen Global Services, LLC, Janssen US Oncology Medical Affairs, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT,
Abstract
Plasma cell leukemia: A multicenter retrospective study of 150 patients.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Department of Internal Medicine, University of Utah, Fred Hutchinson Cancer Research Center,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients.Org: HealthTree Foundation, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT,